Stock Research: NovoCure

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

NovoCure

NSQ:NVCR JE00BYSS4X48
4
  • Value
    32
  • Growth
    5
  • Safety
    Safety
    8
  • Combined
    4
  • Sentiment
    66
  • 360° View
    360° View
    4
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

NovoCure Limited is a global oncology company developing Tumor Treating Fields (TTFields) devices. The company operates in the medical device industry. It operates globally, with a license to market Optune in China, Hong Kong, Macau, and Taiwan. In the last fiscal year, the company had a market cap of $1,887 million, profits of $468 million, and revenue of $605 million, with 1488 employees.

more

ANALYSIS: With an Obermatt 360° View of 4 (better than 4% compared with alternatives), overall professional sentiment and financial characteristics for the stock NovoCure are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for NovoCure. The consolidated Sentiment Rank has a good rank of 66, which means that professional investors are more optimistic about the stock than for 66% of alternative investment opportunities. But all other ranks are below average. The consolidated Value Rank has a rank of 32, which means that the share price of NovoCure is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. The consolidated Growth Rank also has a low rank of 5, meaning that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth, and stock returns. This means that growth is lower than for 5% of competitors in the same industry. Finally, the consolidated Safety Rank has a riskier rank of 8 which means that the company has a riskier financing structure than 92% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Index
NASDAQ
D.J. US Medical Equipment
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 7-May-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
32 20 27 11
Growth
5 80 19 55
Safety
Safety
8 7 25 12
Sentiment
66 30 1 10
360° View
360° View
4 9 1 1
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
35 51 28 3
Opinions Change
50 40 9 26
Pro Holdings
n/a 23 6 72
Market Pulse
53 63 12 38
Sentiment
66 30 1 10
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
32 20 27 11
Growth
5 80 19 55
Safety Safety
8 7 25 12
Combined
4 17 6 6
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
34 27 46 3
Price vs. Earnings (P/E)
95 4 4 4
Price vs. Book (P/B)
10 11 28 12
Dividend Yield
1 1 1 1
Value
32 20 27 11
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
38 1 33 52
Profit Growth
6 74 6 52
Capital Growth
5 100 98 90
Stock Returns
41 84 3 7
Growth
5 80 19 55
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
36 1 6 12
Refinancing
23 62 93 67
Liquidity
23 7 8 4
Safety Safety
8 7 25 12

Similar Stocks

Discover high‑ranked alternatives to NovoCure and broaden your portfolio horizons.

Strabag

VIE:STR
Country: Austria
Industry: Construction & Engineering
Size: X-Large
Full Stock Analysis

Philips

AEX:PHIA
Country: Netherlands
Industry: Health Care Equipment
Size: X-Large
Full Stock Analysis

ENGIE

PAR:ENGI
Country: France
Industry: Multi-Utilities
Size: Large
Full Stock Analysis

Pan African

LSE:PAF
Country: United Kingdom
Industry: Gold Production
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

Only the professional market sentiment is positive. The stock is expensive, has low growth, and low financial safety. This is a weak investment proposition. Only a small, highly-speculative investment may be justified by investors who strongly believe the positive sentiment points to an positive future.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: